NICE TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. (Decision date - December 2021).
NICE TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. (Decision date - December 2021).
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
